X

Trial Profile

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Frexalimab (Primary) ; Frexalimab (Primary)
Indications Systemic lupus erythematosus
Focus Proof of concept; Therapeutic Use
Acronyms APATURA
Sponsors Sanofi

Most Recent Events

10 May 2024 Planned End Date changed from 1 Sep 2025 to 30 Nov 2026.
10 May 2024 Planned primary completion date changed from 9 Jun 2025 to 7 Sep 2025.
15 Nov 2023 Planned End Date changed from 30 Jan 2025 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com